Telik (TELK) suffered a 71% freefall after the California-based biotech announced two disappointing late-stage clinical studies of its experimental cancer drug Telcyta. The trials, which compared the drug to existing therapies in advanced nonsmall-cell lung cancer and ovarian cancer, both failed to meet their primary endpoints of statistically significant improvement in overall survival. Shares were plunging $11.48 to $4.78.
Tecumseh Products (TECUA) jumped on an upgrade by a Robert W. Baird analyst to neutral from underperform. Shares of the Michigan-based compressor-products maker were up $1.99, or 12%, to $18.54.
EpiCept (EPCT) gained after the Tarrytown, N.Y.-based pharmaceutical company said it will license the rights to its back-pain treatment, a transdermal patch containing bupivacaine, for up to $1.9 million to Durect (DRRX). The licensee, a drugmaker based in Cupertino, Calif., will pay Epicept $1 million up front and an additional $9 million in milestone payments, plus royalties on future sales. EpiCept shares were up 13 cents, or 9.4%, to $1.52. Durect shares were slipping 4 cents, or 0.9%, to $4.45.
Adventrx Pharmaceuticals (ANX) shares swelled on news that the Food and Drug Administration had approved clinical testing of its proposed cancer drug ANX-530, deeming it to be bioequivalent to Navelbine, an existing cancer treatment approved for use in nonsmall-cell lung cancer. The San Diego company expects patient recruitment for the initial study to begin in January. Shares were gaining 13 cents, or 4.9%, to $2.77.